:: Library Catalog

Imagen de Portada

Guardado en:

Detalles Bibliográficos
Autor principal:	Iskandar Idris
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Diabetes, Obesity and Metabolism Now
Acceso en línea:	https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1002/doi2.89
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
por: Iskandar Idris
Publicado: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
por: Iskandar Idris
Publicado: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
por: Iskandar Idris
Publicado: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
por: Iskandar Idris
Publicado: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
por: Iskandar Idris
Publicado: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
por: Iskandar Idris
Publicado: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
por: Iskandar Idris
Publicado: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
por: Iskandar Idris
Publicado: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
por: Iskandar Idris
Publicado: (2024)

Epigenetic changes shown to cause type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
por: Iskandar Idris
Publicado: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
por: Iskandar Idris
Publicado: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
por: Iskandar Idris
Publicado: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
por: Iskandar Idris
Publicado: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
por: Iskandar Idris
Publicado: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
por: Iskandar Idris
Publicado: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
por: Iskandar Idris
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Issue Information
Publicado: (2024)

Association of GLP1 ‐receptor agonist use with liver disease progression, major cardiovascular events, and mortality in people with hepatic steatosis and diabetes
por: Suleiman Al Ashi, et al.
Publicado: (2025)

Metabolic dysfunction‐associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes
por: Chloë Aernouts, et al.
Publicado: (2024)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
por: Iskandar Idris, et al.
Publicado: (2025)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
por: Fu‐Shun Yen, et al.
Publicado: (2025)

Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
por: Dario Giugliano, et al.
Publicado: (2025)

Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
por: Claire H. Parker, et al.
Publicado: (2025)

Trends in mortality and hospitalisations for cardiovascular, kidney and liver disease in people with type 2 diabetes in England, 2009–2019
por: Naomi Holman, et al.
Publicado: (2025)

Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity
por: Andy Bowe, et al.
Publicado: (2025)

Association of device measured physical activity with liver fat and stiffness in people with type 1 diabetes
por: Ebaa Al Ozairi, et al.
Publicado: (2025)

Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study
por: Yu Peng, et al.
Publicado: (2025)

Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
por: Claudio Maffeis, et al.
Publicado: (2024)

Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
por: Lucas A. Mavromatis, et al.
Publicado: (2025)

Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis
por: Amanda R. Purcell, et al.
Publicado: (2025)

Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
por: Frederick Berro Rivera, et al.
Publicado: (2024)